|
199 Companies |
|
329 Products |
|
329 Products |
|
164 Mechanisms of Action |
|
13 Trials |
|
3299 News |
|
| «12...56575859606162636465666768» |
- NovoEight (turoctocog alfa) / Novo Nordisk
Trial completion: A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 (clinicaltrials.gov) - Oct 3, 2011
P1, N=6, Completed, Sponsor: Novo Nordisk
Recruiting --> Completed
- | Jakafi (ruxolitinib) / Novartis, Incyte
New P2 trial: Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis (clinicaltrials.gov) - Oct 2, 2011
P2, N=45, Completed, Sponsor: Incyte Corporation
- ||| Biostate (factor VIII/von Willebrand factor) / CSL Behring
New P3 trial: Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development (clinicaltrials.gov) - Sep 29, 2011
P3, N=20, Recruiting, Sponsor: CSL Behring
- |||||||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
New P3 trial: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Sep 28, 2011
P3, N=60, Recruiting, Sponsor: Amgen
- Enrollment closed: Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants (clinicaltrials.gov) - Sep 28, 2011
P1, N=110, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Active, not recruiting
- ||||||| NovoEight (turoctocog alfa) / Novo Nordisk
Trial completion: guardian (clinicaltrials.gov) - Sep 27, 2011
P3, N=150, Completed, Sponsor: Novo Nordisk
No longer recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Wilate (human factor VIII/von Willebrand factor) / Octapharma
Enrollment open, Surgery: WONDERS: Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery (clinicaltrials.gov) - Sep 26, 2011
P3, N=41, Recruiting, Sponsor: Octapharma
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Empliciti (elotuzumab) / AbbVie, BMS
Biomarker, New P2 trial, Monotherapy: Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma (clinicaltrials.gov) - Sep 26, 2011
P2, N=40, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- | abexinostat (CG-781) / Xynomic
Trial completion, Metastases: Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients (clinicaltrials.gov) - Sep 26, 2011
P1, N=36, Completed, Sponsor: Pharmacyclics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- NovoEight (turoctocog alfa) / Novo Nordisk
Enrollment change: A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A (clinicaltrials.gov) - Sep 25, 2011
P1, N=4, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed N=10 --> 4
- NovoEight (turoctocog alfa) / Novo Nordisk
Trial completion: A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A (clinicaltrials.gov) - Sep 25, 2011
P1, N=4, Completed, Sponsor: Novo Nordisk
N=10 --> 4 Recruiting --> Completed
- | Benlysta (belimumab) / GSK
New P2 trial: A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. (clinicaltrials.gov) - Sep 22, 2011
P2, N=48, Not yet recruiting, Sponsor: GlaxoSmithKline
- | Farydak (panobinostat) / Secura Bio
New P1/2 trial, Combination therapy: Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - Sep 22, 2011
P1/2, N=38, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Enrollment change: Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) (clinicaltrials.gov) - Sep 21, 2011
P1/2, N=58, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed N=104 --> 58
- ||| Promacta (eltrombopag) / Novartis
Clinical: Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=280, Completed, Sponsor: GlaxoSmithKline
- | marzeptacog alfa (CB 813d) / GC Biopharma
New P1 trial: Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia (clinicaltrials.gov) - Sep 21, 2011
P1, N=24, Recruiting, Sponsor: Pfizer
- ||| Doptelet (avatrombopag) / SOBI
New P3 trial: Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) (clinicaltrials.gov) - Sep 20, 2011
P3, N=49, Completed, Sponsor: Eisai Inc.
- Cytovene (ganciclovir) / Roche
Trial completion: Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant (clinicaltrials.gov) - Sep 19, 2011
P2, N=61, Completed, Sponsor: City of Hope Medical Center
N=104 --> 58 Active, not recruiting --> Completed
- | Doptelet (avatrombopag) / SOBI
New P1 trial: Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. (clinicaltrials.gov) - Sep 18, 2011
P1, N=36, Completed, Sponsor: Eisai Inc.
- ||| RG7598 / Roche
Enrollment open: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 18, 2011
P1, N=76, Recruiting, Sponsor: Genentech
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| clodronate disodium / Generic mfg.
Trial completion, Adherence: BONA: Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment (clinicaltrials.gov) - Sep 18, 2011
P=N/A, N=147, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: TaCyDexVMP7: Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma (clinicaltrials.gov) - Sep 15, 2011
P4, N=40, Completed, Sponsor: PETHEMA Foundation
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: GEM05 for Patients With Multiple Myeloma More Than 65 Years Old (clinicaltrials.gov) - Sep 15, 2011
P3, N=260, Completed, Sponsor: PETHEMA Foundation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial: The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass (clinicaltrials.gov) - Sep 14, 2011
P4, N=100, Recruiting, Sponsor: Maine Medical Center
- | lenalidomide / Generic mfg.
Enrollment closed: IFM2005-02: Maintenance Therapy Using Lenalidomide in Myeloma (clinicaltrials.gov) - Sep 14, 2011
P3, N=614, Active, not recruiting, Sponsor: University Hospital, Toulouse
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
New P3 trial: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) - Sep 12, 2011
P3, N=24, Terminated, Sponsor: Eisai Inc.
- New P3 trial: PLEX-RCT: The Plasma Large-Volume Exchange RCT (clinicaltrials.gov) - Sep 11, 2011
P3, N=0, Withdrawn, Sponsor: London Health Sciences Centre
- ||| RG7598 / Roche
New P1 trial: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 11, 2011
P1, N=76, Recruiting, Sponsor: Genentech
- Zolinza (vorinostat) / Merck (MSD)
Enrollment open, Combination therapy: Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) (clinicaltrials.gov) - Sep 11, 2011
P1/2, N=30, Recruiting, Sponsor: University Hospital Freiburg
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| cyclophosphamide / Generic mfg., pomalidomide / Generic mfg.
Combination therapy: Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide (clinicaltrials.gov) - Sep 8, 2011
P1/2, N=82, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- || gandotinib (LY 2784544) / Eli Lilly
Enrollment change: A Study in Myeloproliferative Disorders (clinicaltrials.gov) - Sep 6, 2011
P1, N=80, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting N=60 --> 80
- lenalidomide / Generic mfg.
HEOR: Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line (clinicaltrials.gov) - Sep 6, 2011
P=N/A, N=120, Recruiting, Sponsor: Hareth Nahi
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg.
New P2 trial: Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma (clinicaltrials.gov) - Sep 6, 2011
P2, N=60, Enrolling by invitation, Sponsor: Karolinska University Hospital
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
Trial completion: A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Sep 5, 2011
P3, N=35, Completed, Sponsor: Bio Products Laboratory
N=60 --> 80 Active, not recruiting --> Completed
- ||| afuresertib (LAE002) / Laekna Therap
New P1 trial, Combination therapy: Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma (clinicaltrials.gov) - Sep 1, 2011
P1, N=90, Recruiting, Sponsor: GlaxoSmithKline
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, IO biomarker: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Sep 1, 2011
P2, N=48, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- New P2 trial, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 31, 2011
P2, N=42, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- cisplatin / Generic mfg., cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 31, 2011
P2, N=140, Completed, Sponsor: University of Arkansas
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| lenalidomide / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Aug 29, 2011
P2, N=53, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- dexamethasone / Generic mfg., carfilzomib / Generic mfg.
Clinical: Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 29, 2011
P1, N=48, Completed, Sponsor: Onyx Pharmaceuticals
Active, not recruiting --> Completed N=86 --> 48
- ||| Zarxio (filgrastim-sndz) / Novartis
Clinical data: Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (clinicaltrials.gov) - Aug 29, 2011
P=N/A, N=1500, Recruiting, Sponsor: Sandoz
- | dexamethasone / Generic mfg., carfilzomib / Generic mfg.
Clinical: Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 29, 2011
P1, N=48, Completed, Sponsor: Onyx Pharmaceuticals
N=86 --> 48 Active, not recruiting --> Completed
- Trial termination: The Influence of "Karate" on Bleeding in Hemophilic Patients. (clinicaltrials.gov) - Aug 28, 2011
P=N/A, N=12, Terminated, Sponsor: Sheba Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Terminated; logistics
- lenalidomide / Generic mfg.
Enrollment open: REVALLO: Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma (clinicaltrials.gov) - Aug 28, 2011
P1, N=13, Recruiting, Sponsor: University Hospital, Bordeaux
Not yet recruiting --> Terminated; logistics Not yet recruiting --> Recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Combination therapy: Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Aug 28, 2011
P1, N=18, Completed, Sponsor: University of Rochester
Not yet recruiting --> Recruiting Recruiting --> Completed
- afuresertib (LAE002) / Laekna Therap
New P2 trial: A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 24, 2011
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
- ||||| Ojjaara (momelotinib) / GSK
New P1/2 trial, IO biomarker: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - Aug 23, 2011
P1/2, N=61, Active, not recruiting, Sponsor: Gilead Sciences
- Trial completion: Imaging in MGUS, SMM and MM (clinicaltrials.gov) - Aug 23, 2011
P2, N=31, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Completed
- || Mozobil (plerixafor) / Sanofi
Enrollment change: Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). (clinicaltrials.gov) - Aug 22, 2011
P=N/A, N=164, Completed, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Completed N=265 --> 164
- ||| Mozobil (plerixafor) / Sanofi
Trial completion: Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). (clinicaltrials.gov) - Aug 22, 2011
P=N/A, N=164, Completed, Sponsor: Genzyme, a Sanofi Company
N=265 --> 164 Enrolling by invitation --> Completed